Pulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy
| ISSN: |
1432-0843
|
|---|---|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Abstract Subclinical and clinical bleomycin-induced pulmary toxicity (BIP) were investigated retrospectively in 9 patients with non-Hodgkin's lymphoma treated by mbination chemotherapy containing bleomycin. A crease in carbon monoxide diffusing capacity (DLCO) is found in 12.8% of patients. The cumulative risk of normal DLCO increased with the increasing total cumulive dose of bleomycin. No significant difference in the e of BIP was observed between patients receiving bleovein/Adriamycin/cyclophosphamide/vincristine/prednine (BACOP; bleomycin given at 10 mg/m2 for 4 weeks) d bleomycin/Adriamycin/cyclophosphamide/vincrise/dexamethasone/methotrexate/folinic acid (mACOD; bleomycin given at 4 mg/m2 for 3 weeks, ethotrexate given at 200 mg/m2. Monitoring for subclinil BIP should be considered in patients with non-Hodg lymphoma even if only a low dose of bleomycin was ven in the presence of other chemotherapeutic agents.
|
| Type of Medium: |
Electronic Resource
|
| URL: |